SCYNEXIS, Inc.
SCYXSCYNEXIS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative antifungal therapies. It is known for its oral antifungal drug, Brexafemme (ibrexafungerp), which is approved for the treatment of certain fungal infections. The company emphasizes research and development to address unmet medical needs in fungal diseases and expand its portfolio of antifungal agents.
Company News
SCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.
A leading company engaged DelveInsight to conduct a comprehensive study on the myopia market, including prevalence, treatment patterns, and market forecasts across the APAC region. DelveInsight's analysis provided strategic insights to help the client optimize its market entry and differentiation strategies.
SCYNEXIS, a biotechnology company, announced upcoming presentations of preclinical data on its second-generation antifungal compound SCY-247 at IDWeek 2024. SCY-247 is in pre-IND development and has shown broad-spectrum antifungal activity, including against multidrug-resistant pathogens.
JERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.
JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Glob...
